KR20240148418A - 전립선암을 치료하는 방법 - Google Patents

전립선암을 치료하는 방법 Download PDF

Info

Publication number
KR20240148418A
KR20240148418A KR1020247030614A KR20247030614A KR20240148418A KR 20240148418 A KR20240148418 A KR 20240148418A KR 1020247030614 A KR1020247030614 A KR 1020247030614A KR 20247030614 A KR20247030614 A KR 20247030614A KR 20240148418 A KR20240148418 A KR 20240148418A
Authority
KR
South Korea
Prior art keywords
olaparib
subject
abiraterone acetate
cancer
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020247030614A
Other languages
English (en)
Korean (ko)
Inventor
진유 강
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20240148418A publication Critical patent/KR20240148418A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247030614A 2022-02-15 2023-02-14 전립선암을 치료하는 방법 Withdrawn KR20240148418A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263268026P 2022-02-15 2022-02-15
US63/268,026 2022-02-15
PCT/EP2023/053555 WO2023156357A1 (en) 2022-02-15 2023-02-14 Methods of treating prostate cancer

Publications (1)

Publication Number Publication Date
KR20240148418A true KR20240148418A (ko) 2024-10-11

Family

ID=85283519

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247030614A Withdrawn KR20240148418A (ko) 2022-02-15 2023-02-14 전립선암을 치료하는 방법

Country Status (11)

Country Link
US (1) US20250134887A1 (https=)
EP (1) EP4479053A1 (https=)
JP (1) JP2025505041A (https=)
KR (1) KR20240148418A (https=)
CN (1) CN118829430A (https=)
AU (1) AU2023220646A1 (https=)
CA (1) CA3250763A1 (https=)
IL (1) IL314798A (https=)
MX (1) MX2024009923A (https=)
TW (1) TW202400267A (https=)
WO (1) WO2023156357A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1633724T3 (pl) 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
US12280049B2 (en) * 2020-08-04 2025-04-22 Astrazeneca Ab Methods of delaying pain progression and treating prostate cancer

Also Published As

Publication number Publication date
US20250134887A1 (en) 2025-05-01
EP4479053A1 (en) 2024-12-25
WO2023156357A1 (en) 2023-08-24
TW202400267A (zh) 2024-01-01
CN118829430A (zh) 2024-10-22
MX2024009923A (es) 2024-08-22
JP2025505041A (ja) 2025-02-19
IL314798A (en) 2024-10-01
CA3250763A1 (en) 2023-08-24
AU2023220646A1 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
Loibl et al. Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: a randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE)
Massard et al. Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer
JP7407880B2 (ja) 前立腺癌の併用療法
de Kouchkovsky et al. Diagnosis and management of neuroendocrine prostate cancer
Wei et al. Efficacy, tolerability, and pharmacokinetics of combined targeted MEK and dual mTORC1/2 inhibition in a preclinical model of mucosal melanoma
Spreafico et al. A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients
Murphy et al. The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer
Takhsha et al. ATG4B inhibitor UAMC-2526 potentiates the chemotherapeutic effect of gemcitabine in a Panc02 mouse model of pancreatic ductal adenocarcinoma
JP2025537840A (ja) 選択的エストロゲン受容体分解薬（ｓｅｒｄ）による乳がんの治療方法
US20250235451A1 (en) Methods of Delaying Pain Progression And Treating Prostate Cancer
Yildirim et al. Outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate
KR20240148418A (ko) 전립선암을 치료하는 방법
Sunkara et al. Poly adenosine diphosphate-ribose polymerase (PARP) inhibitors in pancreatic cancer
Gandupalli et al. Recent advancements in therapeutic biomarkers, associated challenges and considerations to overcome these challenges in prostate cancer
Garcia‑Saenz et al. SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (UPDATE 2025)
JP2025508399A (ja) 脳がんの処置のためのニラパリブの使用
Lakritz et al. Activity of platinum chemotherapy in men with prostate cancer with and without DNA damage repair mutations
Niu et al. Efficacy and toxicities of doxorubicin plus ifosfamide in the second-line treatment of uterine leiomyosarcoma
Heidenreich et al. Modern management of castration-resistant prostate cancer
US20250275978A1 (en) Use of onvansertib as monotherapy and in combination with cetuximab in treating ras wild-type colorectal cancer
Ma et al. The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
WO2025188679A1 (en) Use of plk1 inhibitor and paclitaxel in treating small cell lung cancer
WO2026096660A1 (en) Plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancer
Lange et al. First-line systemic treatment with gefitinib in stage IV non-small cell lung cancer
CN116056707A (zh) 治疗前列腺癌的方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202